Griset (Anastrozole)

Griset (anastrozole) is indicated for the management of hormone‑dependent breast cancer in postmenopausal patients.

• Adjuvant therapy after surgery to reduce risk of recurrence.
• Treatment of advanced or metastatic estrogen‑receptor‑positive breast cancer.
• Used in combination with other endocrine therapies as directed by a specialist.
• May be prescribed for off‑label hormonal conditions under clinical supervision.
• Part of hormone‑blocking regimens in clinical trials for breast cancer.

The safety profile of Griset reflects the pharmacology of anastrozole, with most patients experiencing mild to moderate events, while rare serious reactions may occur.

Common

• Hot flashes or night sweats.
• Joint or muscle aches.
• Fatigue and mild nausea.
• Decreased bone mineral density over long‑term use.
• Mood changes or mild depression.
• Decreased libido or sexual dysfunction.
• Nausea with occasional vomiting.
• Dry mouth or altered taste.

Serious

• Severe allergic reaction such as rash, swelling, or difficulty breathing.
• Elevated liver enzymes indicating potential hepatotoxicity.
• Deep vein thrombosis or pulmonary embolism.
• Osteoporotic fractures due to bone loss.
• Cardiovascular events such as hypertension or arrhythmia.
• Severe liver injury presenting as jaundice.

When prescribing Griset, clinicians consider several precautionary measures to ensure patient safety and optimal therapeutic outcome.

• Assess baseline bone mineral density because anastrozole can accelerate bone loss.
• Review liver function tests prior to initiation and periodically during therapy.
• Verify postmenopausal status; anastrozole is not indicated for premenopausal women without ovarian suppression.
• Monitor lipid profile, as estrogen reduction may affect cholesterol levels.
• Counsel patients on the importance of calcium and vitamin D supplementation.
• Evaluate for any history of thromboembolic disease before starting treatment.

Griset may interact with other medicines that influence hormone metabolism or share similar safety concerns.

Avoid

• Concomitant use of strong CYP3A4 inducers such as rifampin, which can lower anastrozole plasma levels.
• Combined therapy with other aromatase inhibitors, as this provides no added benefit and increases toxicity risk.
• Simultaneous administration of estrogen‑containing products, which counteract the intended estrogen‑lowering effect.
• Avoid concurrent use of tamoxifen, as the combination may produce antagonistic effects on estrogen pathways.

Use with caution

• Anticoagulants, because reduced estrogen may affect clotting factors.
• Statins or other lipid‑lowering agents, given potential additive effects on cholesterol.
• Hormone replacement therapy, requiring close monitoring of hormonal balance.